McLaughlin PJ, Keiper CL, Verderame MF, Zagon IS. Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure. Am J Physiol Regul Integr Comp Physiol 302: R1084-R1090, 2012. First published February 15, 2011 doi:10.1152/ajpregu.00670.2011The opioid growth factor (OGF) and its receptor, OGFr, play a regulatory role in cell proliferation, and maintain homeostasis through a tonically active negative feedback mechanism. To directly evaluate the repercussion of increased OGFr expression and consequent gain-of-function in epithelium, bovine keratin 5 promoter elements were used to direct the expression of OGFr to skin in a tetracycline-regulated manner. Three founder lines overexpressing OGFr (OGFrTG/K5-tTA) were established. Evidence for increased OGFr in the epithelium included a three-fold increase in OGFr binding activity, as well as significant increases in OGFr protein, as monitored by semiquantitative immunohistochemistry. DNA synthesis in target epithelium, including cornea, tongue, and skin of transgenic mice was decreased 41% to 80% from wild-type littermates; the liver, a nonepithelial organ, was not altered. Decreased DNA synthesis in corneal epithelium induced by transgenic expression of OGFr was further reduced by treatment with exogenous OGF but reversed by exposure to the opioid antagonist, naloxone. The number of cell layers in both epidermis and cornea of OGFrTG/K5-tTA animals was reduced nearly 45% from wild-type mice. Full-thickness wounds in mice overexpressing OGFr healed 37% to 75% slower than wild-type littermates. These data demonstrate for the first time that stable genetic amplification of OGFr downregulates homeostatic cell proliferation, as well as pathophysiological processes with respect to wound repair. These mice also can serve as a valuable model to dissect the mechanism of OGF-OGFr action and may be important in understanding the etiology, pathogenesis, and treatment of epithelium-related diseases.
]-enkephalin, OGF is an endogenous opioid peptide that is constitutively expressed, autocrine-produced, and secreted (42) , and internalized by clathrin-mediated endocytosis (4) . The OGF-OGFr complex tonically regulates the G 1 /S interface of the cell cycle by modulating cyclin-dependent kinase inhibitory pathways in a negative feedback loop (5) (6) (7) (8) (9) . Specifically, it has been shown that OGF increases p16 and/or p21 protein expression by way of the Rb pathway, and the equilibrium of OGF-OGFr interactions is essential in maintaining the normal physiological state of cell proliferation.
The action of OGF is mediated by the nuclear associated receptor OGFr (7, 36, 42) . The gene for OGFr is at least 9 kb in length, encodes a 677-amino acid protein, and has a chromosomal location in humans of 20q13.3 (39, 40, 42, 43) . Although OGFr has pharmacological properties (e.g., recognizes opioids, naloxone reversibility, and stereospecificity) similar to classical opioid receptors (i.e., MOR, ␦DOR, and KOR), it shares no homology with classical opioid receptors in either nucleotide or amino acid sequences. OGF-OGFr regulation of cell proliferation involves nucleocytoplasmic trafficking from the outer nuclear envelope to the nucleus and requires nuclear localization signals and transport by karyopherin ␤ and Ran (7, 8, 36) .
Although the OGF-OGFr axis is in a constant state of adaptive response to an ever-changing cellular/tissue environment, modulation of the OGF-OGFr axis has been documented pharmacologically (e.g., imiquimod and naltrexone) or molecularly (e.g., siRNA), and this modulaton of the OGF-OGFr axis results in increases or decreases in cell proliferation. The biological ramifications of stable modification of OGFr in the genetic make-up of an animal to produce a gain-in-function is unknown. The present investigation explores the question of the effects of genetically modifying mice to have an overexpression of OGFr in the epithelium with respect to homeostatic cellular renewal and to wound healing.
MATERIALS AND METHODS

Generation of Transgenic Mice
Transgenic mice were generated following standard techniques (18) . To construct a doxycycline-inducible OGFr transgene cassette (TMILAOGFr), full-length rat OGFr cDNA was subcloned at the EcoRI and XbaI sites downstream of tet operator sequences (Fig. 1) . Translation of a luciferase reporter gene by an internal ribosome entry site (IRES) was used as a marker for transgene expression. The TMILA vector was kindly provided by Dr. Edward Gunther (17) . Tg(tet)OGFr mice were generated by microinjection of TMILA-OGFr vector into B6D2F1 zygotes generated by crossing C57BL/6 females with DBA/2J males at The Pennsylvania State University Transgenic Facility in University Park, PA.
Seven of eight founder transgenic lines had germ line transmission as detected by PCR and gel electrophoresis. Male and female Tg(tet)OGFr mice were crossed with transgenic mice carrying TA-K5 (a gift of Dr. David Feith, The Pennsylvania State University College of Medicine, Hershey, PA; hereafter, referred to as K5 mice), which allowed OGFr to be expressed in epithelium under the keratin 5 (K5) promoter (16) . Offspring were screened by PCR at 10 days of age, and double transgenics designated OGFrTG/K5-tTA were used in subsequent studies.
Transgenic mice were housed initially in plastic isolators and then were returned to general housing conditions; all animals received standard rodent chow and water ad libitum. The (tet)OGFr regulator was "tet-off"; thus, doxycycline was not added to the diet. Normal C57BL/6 mice served as wild-type mice; in some cases, littermates carrying only one transgene were utilized. All procedures were approved by The Pennsylvania State University College of Medicine Animal Care and Use Committee.
Initially seven founder lines were established, and OGFrTG/K5-tTA double-transgenic mice were screened at 25-40 days of age for whole body expression of OGFr using the Xenogen phosphoimager system IVIS 50 (Caliper-Perkin Elmer, Hopkinton, MA). Six of the seven founder lines showed Xenogen luciferase expression. Three mouse founder lines with double transgenic offspring having elevated luciferase expression were selected for expansion, and 3-10 mice from one or more lines were used for further characterization.
Tissue-Specific Evaluation of OGFr Overexpression
OGFr binding assays. Standard pharmacological binding assays (10) were conducted on the gastrointestinal tract of OGFrTG/K5-tTA mice from founder lines A, D, and G. At 40 days of age, mice were euthanized, and a 12-to 15-cm segment of the small intestine was removed beginning at the duodenal-jejunal junction. Tissue was flushed, rinsed in Tris buffer with protease inhibitors, and immediately frozen for assay.
DNA Synthesis
DNA synthesis was measured by BrdU incorporation (10, 14) . At 40 days of age, male or female double transgenic mice in the A, D, and G lines, as well as wild-type animals from each founder line, were injected with 100 mg/kg BrdU (intraperitoneally) at 6 and 3 h prior to euthanasia. Cornea, tongue, and skin samples were collected, fixed in formalin, and processed for paraffin embedding (12) (13) (14) . Sections were stained using anti-BrdU (1:200; Invitrogen) and counterstained with hematoxylin. Cell counts were made in the peripheral cornea, dorsal surface of the tongue, and skin of the back.
Receptor Mediation
To determine whether the overexpressed OGF receptors were functional and able to be blocked in a pharmacological manner, transgenic and wild-type mice were injected once with 20 mg/kg naloxone, a short acting opioid antagonist with less than a 2-h duration, and the animals were euthanized 4 h later; 100 mg/kg ip BrdU was injected 3 h prior to euthanasia. Sections of peripheral corneal epithelium were counted for BrdU incorporation.
OGF-Treatment of OGFrTG/K5-tTA Mice
To assess the functionality (and responsiveness) of OGFr overexpression, transgenic mice were injected intraperitoneally with 10 mg/kg OGF 6 h prior to euthanasia, and 100 mg/kg BrdU (intraperitoneally) at 6 and 3 h prior to euthanasia (13, 14) . Corneas were removed and processed for paraffin sectioning; sections were then stained with anti-BrdU, as described above. Wild-type mice injected with OGF, as well as double transgenic OGFrTG/K5-tTA and wildtype mice receiving saline, were included as controls.
Immunohistochemistry
Mice (n ϭ 2 or 3 per mouse line) were euthanized, and specimens of dorsal skin and tongue were removed and frozen in isopentane chilled on dry ice. Tissues were sectioned at 10 m; fixed and permeabilized with ice-cold ethanol (95% vol/vol) and acetone (100%); and stained with anti-OGFr antibodies, according to published procedures (10) . Polyclonal antibodies to OGFr were generated in the laboratory and have been fully characterized (35) . Sections of skin incubated with secondary antibody only served as a negative control. To evaluate the relative expression of OGFr, images were taken at the same exposure time with care not to photobleach samples. Mean intensity of staining (mean gray value) was determined for the basal layer of the epithelium from 13-25 sections sampled from 2 or 3 mice for each of the transgenic mouse lines; 5-13 measurements from each corresponding wild-type line were collected and averaged. Controls included preparations incubated with secondary antibodies only.
Number of Cell Layers in the Epidermis
Using hematoxylin and eosin-stained sections of skin and cornea from mice in the A and D OGFrTG/K5-tTA lines, as well as wild-type littermates, we counted the number of cell layers in the epidermis and peripheral cornea using bright-field microscopy. Ten random samples from 3 mice/group were evaluated.
Full-Thickness Wounds
OGFrTG/K5-tTA mice (n ϭ 3 per group) in the A line as well as wild-type mice were selected at 20 wk of age, and a 15-mm diameter area was shaved on the dorsum. Mice were anesthetized by intraperitoneal injection of ketamine (40 mg/kg), xylazine (20 mg/kg), and two 4-mm full-thickness circular excisional skin wounds were made in the shaved area to the level of the panniculus muscle using an Acupunch (Acuderm, Fort Lauderdale, FL). Wounds were placed on the right and left scapular region. To minimize the effects of diurnal rhythm, surgery was performed between 1500 and 1600. All wounds were left uncovered.
Wound size was monitored by photographing the mice with a digital camera mounted on a tripod set 20 cm from the surface; a ruler was photographed with each wound. Animals were sedated with regulated 3% isoflurane for photography. Photographs were taken immediately after surgery, and 16, 24, 40, 48, 64, 72, and 144 h later. The area of each wound was analyzed using Optimas 6.2 (Optimas ), and the percent of wound remaining was calculated.
Statistical Analyses
Data are expressed as the means Ϯ SE. Data were analyzed using the Student's t-test, or ANOVA with subsequent comparisons made with Newman-Keuls tests. All statistical comparisons were made using Prism software (GraphPad Software, San Diego, CA).
RESULTS
Generation of OGFrTG/K5-tTA Mice Resulted in Viable Offspring with No Phenotypic Abnormalities
All of the germline transmitted OGFrTG/K5-tTA founder mouse lines (i.e., A-E, G, H) were viable, and females from each line were fertile. No problems with fertility or mortality were noted. Pups from each founder were screened for the presence of OGFrTG by PCR. Three PCR reactions were completed on each specimen to screen for luciferase and OGFr, and an internal control, adenamatous polyposis coli (APC). To evaluate the role of OGFr in epithelial cell proliferation and wound healing, transgenic mice that overexpressed OGFr targeted in epithelium were created by crossing OGFrTG mice with K5 mice.
Double transgenic OGFrTG/K5-tTA mice were identified by PCR reactions of tail snips taken at 10 days of age. Double transgenic animals were observed at the expected ratio of 1:4; thus, about one pup per litter was used for study or allowed to grow up for further breeding. On the basis of several assays evaluating levels of OGFr expression, including xenogen images (Fig. 2) and receptor binding assays (Fig. 3) , founder mouse lines A, D, and G were further characterized. At least 6 OGFrTG/K5-tTA mice from each mouse line were studied, as well as 6 -10 wild-type pups from each clonal line.
No gross physical or behavioral abnormalities were observed in any of the founder animals or their double transgenic progeny. Xenogen images of double transgenic mouse lines A, D, and G, and wild-type mice are presented in Fig. 2 (Fig. 3A) . Binding capacity of OGFr in intestinal preparations of the OGFrTG/K5-tTA mice was nearly three-fold greater than all wild-type mice (7.5 Ϯ 1.3 fmol/mg protein) (Fig. 3B) . However, binding affinity (K d ) of the intestinal tissues in the OGFrTG/K5-tTA mice ranged from 3.9 Ϯ 1.4 to 7.5 Ϯ 0.2 nM and were comparable to those of wild-type animals (3.4 Ϯ 0.8 nM).
OGFr was increased in skin and tongue of OGFrTG/K5-tTA mice. Sections of the skin and tongue of OGFrTG/K5-tTA and wild-type mice were stained with anti-OGFr and semiquantitatively assessed for expression of OGFr (Fig. 4) . Immunohistochemical distribution of OGFr did not differ between wildtype mice and those transgenic for overexpression of OGFr, and it was detected largely in the cytoplasm, but with a Fig. 5 . DNA synthesis monitored with BrdU in tissues of wildtype (Wt) and OGFrTG/ K5-tTA mice overexpressing OGFr. A: cells in the cornea, tongue, and skin of transgenic mice exhibit significant decreases in BrdU labeling in contrast to Wt animals, but DNA synthesis did not differ in the brain or the liver. B: administration of the opioid antagonist naloxone reversed the decreased BrdU labeling in the peripheral corneal epithelium of transgenic mice overexpressing OGFr, but naloxone alone had no effect on DNA synthesis. C: administration of OGF to transgenic mice overexpressing OGFr reduced DNA synthesis in the peripheral corneal epithelium to an even greater extent than baseline levels for these animals. Histograms represent means Ϯ SE for 10 random measurements/section, two sections/mouse, and 2-4 mice/line except for panel B, where 1-4 mice/line were used. Significantly different from Wt at *P Ͻ 0.05, **P Ͻ 0.01, or ***P Ͻ 0.001, or from the transgenic mice receiving saline at ϩP Ͻ 0.05. speckling of immunoreactivity in the nucleus (Fig. 4A) . However, the quantity of OGFr in both the skin and the tongue of OGFrTG/K5-tTA mice ranged from 12% to 54% greater than that of wild-type animals (Fig. 4, B and C) .
DNA Synthesis in Epithelia of Transgenic Mice Was Downregulated
Homeostatic levels of DNA synthesis were reduced in transgenic mice. DNA synthesis as measured by BrdU incorporation revealed marked reductions in the homeostatic labeling in the peripheral corneal epithelium, tongue, and skin of OGFrTG/K5-tTA double-transgenic mice relative to littermate wild-type mice (Fig. 5A) . Compared with basal BrdUlabeling rates for these diverse epithelial-related structures, a reduction in all double-transgenic lines of 41% to 80% was noted. To examine the specificity of overexpression of OGFr in epithelial cells with respect to DNA synthesis, we examined liver tissue; the K5 promoter is not known to be active in the liver (28) . Compared with that of wild-type animals ( Fig. 5A) , no changes in levels of DNA synthesis were noted in the liver of OGFrTG/K5-tTA mice derived from line A (Fig. 5A) .
The reduction in DNA synthesis in the corneal epithelium of transgenic mice was receptor mediated. To evaluate whether the changes in DNA synthesis in the transgenic mice were opioid receptor mediated, the opioid antagonist naloxone was administered to wild-type and transgenic OGFrTG/K5-tTA mice (Fig. 5B) . In contrast to DNA synthesis in the peripheral corneal epithelium of wild-type mice (13.6 Ϯ 1.0), there was a 38% decrease in the peripheral corneal epithelium of OGFrTG/ K5-tTA mice derived from line D. However, OGFrTG/K5-tTA mice exposed to naloxone had levels of DNA synthesis in the peripheral corneal epithelium that were comparable to controls. No differences in BrdU incorporation were detected between wild-type mice receiving vehicle and those exposed to naloxone.
Exogenous OGF treatment of transgenic mice overexpressing OGFr reduced DNA synthesis in the corneal epithelium. The effect of adding exogenous OGF to mice overexpressing OGFr on DNA synthesis was investigated in the peripheral corneal epithelium (Fig. 5C) . Compared with wild-type mice with values of DNA synthesis of 12.8 Ϯ 0.8% BrdU-positive cells in the basal layer of the peripheral corneal epithelium, line D OGFrTG/K5-tTA animals exposed to vehicle had 3.8 Ϯ 1.3% BrdU-positive cells. OGFrTG/K5-tTA animals treated with OGF exhibited a significant further reduction in DNA synthesis.
The Number of Cell Layers in the Epidermis and Peripheral Cornea Was Decreased in Mice Overexpressing OGFr
Assessment of the number of cell layers in the epidermis of OGFrTG/K5-tTA mice in line A was 0.9 Ϯ 0.2 layers compared with wild-type counterparts with 3.6 Ϯ 0.2 layers. Similarly, the number of cell layers in line D OGFrTG/K5-tTA mice was 1.1 Ϯ 0.2 layers in contrast to that of 3.7 Ϯ 0.3 layers in corresponding wild-type littermates. In both lines of mice, the difference between transgenic and wild-type mice with respect to the number of cell layers was statistically significant (P Ͻ 0.001).
The number of cell layers counted in the peripheral cornea of transgenic mice in line A and respective wild-type mice revealed that transgenic mice had only 2.3 Ϯ 0.1 cell layers compared with 4.2 Ϯ 0.2 cell layers in wild-type mice (P Ͻ 0.001). 
Wound Healing in Mice Overexpressing OGFr Is Delayed Compared with Wild-Type Littermates
Skin wounds of 4-mm diameter, created in line A OGFrTG/ K5-tTA mice overexpressing OGFr had significantly larger residual wounds than wild-type littermates, with residual wounds being 41% to 75% (Fig. 6, A and B) . The delays in wound repair of OGFrTG/K5-tTA mice were noted as early as 16 h, and continued for at least 3 days.
DISCUSSION
The OGF-OGFr axis plays an important role in governing cell proliferation. We now provide the major insight that targeted overexpression of OGFr by changing the genetic constitution of mice, yielding a sustained overactivation of OGFr in epithelium, has profound effects on homeostatic cellular renewal and wound repair. Evidence for the elevated expression of OGFr in epithelium included a pronounced increase in the epithelium with bioluminescent imaging, an approximate three-fold increase in the number, but not affinity, of OGFr in receptor-binding studies, and significantly more OGFr immunoreactivity, as monitored by semiquantitative immunohistochemistry. Moreover, three founder lines exhibited similar findings, animals from many litters were sampled, a number of organs with epithelium demonstrated similar characteristics, and an endodermal derivative was not altered by genetic modification of OGFr directed to epithelium. With regard to gross physical or behavioral characteristics, an amplification of OGFr in the epithelium did not reveal any irregularities. However, an increase in OGFr expression in the epithelium did result in a marked decrease in DNA synthesis of the cornea, tongue, and skin, and the number of cell layers comprising the epithelium of skin. This potentiation of a repression in cellreplicative activity in the epithelium of animals overexpressing OGFr was receptor mediated, with the opioid antagonist naloxone blocking the effects of endogenous opioids on the increased number of receptors. Moreover, the excess OGFr in mice, genetically engineered to have an increased expression of this gene, heightened the response of exogenous OGF by even further, decreasing DNA synthesis. Finally, pathophysiology studies with wound healing showed that an overexpression of OGFr in skin markedly delayed wound repair. Thus, these results reveal for the first time that changing the genetic composition of an organism with respect to OGFr has important repercussions on the integrity and functionality of a biological pathway regulating cell proliferation.
The present observations on the effects of an abundance of OGFr in epithelial cells with respect to cell proliferation and wound repair are consonant with previous reports using pharmacological tools, as well as molecular manipulation of OGFr. Earlier studies have reported that transient transfection of OGFr cDNA into rat corneal epithelial cells using a gene gun suppressed the normal state of DNA synthesis, as well as delayed wound healing (37, 38) . Moreover, studies in squamous cell carcinoma (21, 22) , ovarian cancer (14) , and pancreatic neoplasia (34, 41) have shown that stable transfection of OGFr cDNA markedly represses neoplasia under both in vitro and in vivo environments. Additionally, upregulation of OGFr by imiquimod (21, 32) or a low dose of naltrexone (LDN) (11, 12, 15, 21) , or the addition of exogenous OGF (1-10, 12-14, 19, 21, 23, 29 -31, 33 ) also can decrease cell proliferation-related events. These data, along with the present investigation with genetically modified mice, whereby a K5 promoter drives OGFr expression, reveal the fundamental nature and direct biological significance of the OGF-OGFr axis as a critical determinant of cell proliferation. Moreover, these transgenic mice provide a valuable model to study the role of OGFr in other epithelial functions related to health and disease.
The OGF-OGFr axis is present and functions in human epithelial cells and tissues to coordinate physiological processes that maintain a steady state of cell proliferation. Given the importance of the OGF-OGFr system in such a crucial biological function, the present findings raise the question of the repercussions arising from a genetically related abundance of OGFr in epithelium. Although we are unaware of a genetic abnormality of OGFr, based on data in this investigation, conceivably, one would anticipate that homeostasis of cell proliferation would be difficult to preserve, if indeed such an irregularity did occur. Moreover, when stimuli, such as wounding or disease are involved, adaptive responses to these changes in the environment will be compromised. Knowing that elevation in OGFr levels can diminish cell proliferation, also speaks to the use of agents to suppress hyperproliferative diseases, as well as neoplasia. For example, imiquimod and resiquimod, as well as the opioid antagonist naltrexone, have been reported to upregulate OGFr and depress cell proliferation. Indeed, clinical trials using OGF alone have shown that treatment with this peptide has a marked antineoplastic effect by extending survival, without toxicity, in patients with pancreatic cancer (24, 26) , as well as mucosal healing in Crohn's patients with LDN (25, 27) .
